WS Investor
14 Sep 2026, 17:10
FDA Approves Shorter Monitoring Period for Amgen’s IMDELLTRA Lung Cancer Treatment
Amgen said the U.S. Food and Drug Administration approved an update to the prescribing information for IMDELLTRA, significantly reducing the recommended monitoring period following the first two doses of the company’s small cell lung cancer therapy.
Under the updated label, patients should be monitored for six to eight hours from the start of their first two infusions, down from the previous recommendation of 22 to 24 hours. Patients will receive a follow-up assessment, including vital signs, the day after each of those doses.
The change could make IMDELLTRA easier to administer outside major treatment centers. Amgen noted that an estimated 80% to 85% of U.S. cancer patients receive care in community oncology settings, where lengthy monitoring requirements can complicate treatment.
IMDELLTRA is a first-in-class targeted immunotherapy designed to bind DLL3 on tumor cells and CD3 on T cells, activating the immune system against DLL3-expressing small cell lung cancer cells. It is approved for adults with extensive-stage small cell lung cancer whose disease has progressed during or after platinum-based chemotherapy.
The FDA decision follows Amgen’s recent announcement of positive overall-survival results from the Phase 3 DeLLphi-305 study evaluating IMDELLTRA with Imfinzi in first-line extensive-stage small cell lung cancer.
Amgen said the U.S. Food and Drug Administration approved an update to the prescribing information for IMDELLTRA, significantly reducing the recommended monitoring period following the first two doses of the company’s small cell lung cancer therapy.
Under the updated label, patients should be monitored for six to eight hours from the start of their first two infusions, down from the previous recommendation of 22 to 24 hours. Patients will receive a follow-up assessment, including vital signs, the day after each of those doses.
The change could make IMDELLTRA easier to administer outside major treatment centers. Amgen noted that an estimated 80% to 85% of U.S. cancer patients receive care in community oncology settings, where lengthy monitoring requirements can complicate treatment.
IMDELLTRA is a first-in-class targeted immunotherapy designed to bind DLL3 on tumor cells and CD3 on T cells, activating the immune system against DLL3-expressing small cell lung cancer cells. It is approved for adults with extensive-stage small cell lung cancer whose disease has progressed during or after platinum-based chemotherapy.
The FDA decision follows Amgen’s recent announcement of positive overall-survival results from the Phase 3 DeLLphi-305 study evaluating IMDELLTRA with Imfinzi in first-line extensive-stage small cell lung cancer.
